ClinicalTrials.gg
Enrolling by invitationNCT07943598DMDUpdated Nov 17, 2026

A Global Phase 2 Extension Study of Brogidirsen in Boys With Duchenne Muscular Dystrophy

A Phase 2 interventional study of Brogidirsen in Duchenne Muscular Dystrophy, Exon 44 and DMD, sponsored by NS Pharma, Inc.. Enrolling by invitation at 17 sites in 7 countries. Open to male participants. Per ClinicalTrials.gov, last updated 2026-11-17.

Sponsored by NS Pharma, Inc. · Phase 2, Interventional, and Treatment

Updated Nov 17, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
20
Allocation
Not applicable
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 10 studies in Muscular Dystrophy, Duchenne by NS Pharma, Inc. — 1 open to participants now, 5 under way, 1 of them phase 3. Muscular Dystrophy, Duchenne · NS Pharma, Inc..

Started
2026
the only one that year
Phase 2
5 of 10
1 open now
Registered
10th of 10
by date

Among the 10 studies in Muscular Dystrophy, Duchenne by NS Pharma, Inc., this one is the only one that started in 2026, is one of 5 in phase 2, and was the 10th registered.

Muscular Dystrophy, Duchenne

481 studies on the registry are indexed under Muscular Dystrophy, Duchenne; 106 are open to participants now.

Browse Muscular Dystrophy, Duchenne studies →

Open to participants now

1 of the 10 studies in Muscular Dystrophy, Duchenne by NS Pharma, Inc. is open now, in 7 countries.

By country, each count listing its studies:

Who these studies take

Of the 65 Muscular Dystrophy, Duchenne studies recruiting now, 30 (46%) set no upper age limit and 33 (51%) stop at 75 or younger; 58 take children under 18; 11 take healthy volunteers.

This study: male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Muscular Dystrophy, Duchenne by NS Pharma, Inc., or all of them as a file.
02

Study summary

This Phase 2, open-label, multi-center extension study will be conducted in boys with DMD who completed the 24-week Treatment Period of Study NS-089/NCNP-02-201. Brogidirsen will be administered by IV infusion once weekly for up to 120 weeks (up to a total of 144 weeks of treatment, including weekly dosing from Part 2 of Study NS-089/NCNP-02-201) or until brogidirsen is commercially available, whichever is earlier.

03

Conditions studied

  • Duchenne Muscular Dystrophy
  • Exon 44
  • DMD

Keywords

  • Exon 44 Skipping
  • DMD
  • Brogidirsen
04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Participant has successfully completed Study NS-089/NCNP-02-201
  2. Participant and parent(s) or legal guardian(s) are willing and able to comply with scheduled visits, product (IP) administration plan, and study procedures
  3. Participant must be on a stable dose of (GC) steroids and is expected to remain on a stable dose of GC steroid treatment for the duration of the study
  4. Other inclusion criteria may apply

Exclusion criteria

Exclusion Criteria:

  1. Participant had an adverse event (AE) in Study NS-089/NCNP-02-201 that, in the judgment of the investigator and/or sponsor, precludes safe use of brogidirsen for the participant in this study
  2. Participant had a treatment other than brogidirsen which was made for the purpose of dystrophin or dystrophin-related protein induction after completion of Study NS-089/NCNP-02-201
  3. Participant is currently taking other drug(s)
  4. Participant is judged by the investigator to be inappropriate for this study for other reasons
  5. Other exclusion criteria may apply
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
20 participants (estimated)

Study arms

  • Experimental
    Brogidirsen

    Drug: Brogidirsen

Interventions

  • DrugBrogidirsen

    Brogidirsen will be administered for up to 120 weeks (up to a total of 144 weeks of treatment, including weekly dosing from Part 2 of Study NS-089/NCNP-02-201) or until Brogidirsen is commercially available, whichever is earlier.

06

What researchers measure

Primary outcomes

  1. Incidence of treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs)

    Time frame: Through study completion, an average of 124 weeks

  2. Change in baseline in the following assessments: 12-lead electrocardiograms (ECGs), Vital signs, Physical and neurological examinations, Clinical laboratory tests

    Time frame: Through study completion, an average of 120 weeks

Secondary outcomes

  1. North Star Ambulatory Assessment (NSAA) score

    The NSAA is a functional scale devised for use in ambulant children with Duchenne muscular dystrophy (DMD). It consists of 17 activities graded 0 (unable to perform), 1(performs with modifications), 2 (normal movement). It assesses abilities necessary to remain ambulant that have been found to progressively deteriorate in untreated DMD patients, as well as in other muscular dystrophies such as Becker Muscular Dystrophy. NSAA Total Score ranges from 0 to 34, with a score of 34 implying normal function.

    Time frame: Through study completion, an average of 120 weeks

  2. Time to Run/Walk 10 Meters (TTRW)

    Time frame: Through study completion, an average of 120 weeks

  3. Time to Stand (TTSTAND)

    Time frame: Through study completion, an average of 120 weeks

  4. Time to Climb 4 Stairs (TTCLIMB)

    Time frame: Through study completion, an average of 120 weeks

  5. Performance of Upper Limb (PUL) 2.0 score

    The PUL 2.0 provides both a total score and sub-scores for the 3 domains (shoulder, middle, and distal) that in DMD are progressively involved with a proximal to distal gradient. The PUL includes 22 items with an entry item to define the starting functional level. The 22 items are subdivided into the high-level shoulder dimension (6 items), middle level elbow dimension (9 items), and distal wrist and hand dimension (7 items). For weaker patients, a low score on the entry item (0-2) means high level items do not need to be performed. Scoring options vary across the scale between 0-1 and 0-2 according to performance. Each dimension can be scored separately with a maximum score of 12 for the high-level shoulder dimension, 17 for the middle level elbow dimension, and 13 for the distal wrist and hand dimension. A total score can be achieved by adding the 3 level scores (maximum total score of 42)

    Time frame: Through study completion, an average of 120 weeks

07

Study locations

17 sites
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Dec 2026; primary completion for Sep 2029, 32 months later.

Of 40 industry-sponsored phase 2 interventional studies under Muscular Dystrophy, Duchenne, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 42. This study's planned 32 months is close to that.

Counting every sponsor, half of 47 studies reached it within 31 months; a quarter within 20 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 3, 2026
First posted
Nov 17, 2026
StartEst.
Dec 16, 2026
Primary completionEst.
Sep 3, 2029
CompletionEst.
Sep 3, 2029
Last update
Nov 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 17, 2026
Show all 1 update
  1. Nov 17, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07943598
Lead sponsor
NS Pharma, Inc.
Collaborators
Nippon Shinyaku Co., Ltd.
Responsible party
Sponsor
First posted
Nov 17, 2026
Start date
Dec 16, 2026 (estimated)
Primary completion
Sep 3, 2029 (estimated)
Completion
Sep 3, 2029 (estimated)
Last update
Nov 17, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion